公开(公告)号：EP2880028B1

公开(公告)日：2020-09-30

申请号：EP13750427.0

申请日：2013-07-31

申请人： Merck Sharp & Dohme Corp.

发明人： HAGMANN, William, K. ,  NARGUND, Ravi, P. ,  BLIZZARD, Timothy, A. ,  JOSIEN, Hubert ,  BIJU, Purakkattle ,  PLUMMER, Christopher, W. ,  DANG, Qun ,  LI, Bing ,  LIN, Linus, S. ,  CUI, Mingxiang ,  HU, Bin ,  HAO, Jinglai ,  CHEN, Zhengxia

IPC分类号： C07D401/14 ,  C07D221/16 ,  C07D401/12 ,  C07F9/40 ,  A61K31/435 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

公开(公告)号：EP2880028A1

公开(公告)日：2015-06-10

申请号：EP13750427.0

申请日：2013-07-31

申请人： Merck Sharp & Dohme Corp.

发明人： HAGMANN, William, K. ,  NARGUND, Ravi, P. ,  BLIZZARD, Timothy, A. ,  JOSIEN, Hubert ,  BIJU, Purakkattle ,  PLUMMER, Christopher, W. ,  DANG, Qun ,  LI, Bing ,  LIN, Linus, S. ,  CUI, Mingxiang ,  HU, Bin ,  HAO, Jinglai ,  CHEN, Zhengxia

IPC分类号： C07D401/14 ,  C07D221/16 ,  C07D401/12 ,  C07F9/40 ,  A61K31/435 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

公开(公告)号：EP2528603A1

公开(公告)日：2012-12-05

申请号：EP11737514.7

申请日：2011-01-25

申请人： Merck Sharp & Dohme Corp.

发明人： CHOBANIAN, Harry ,  LIN, Linus, S. ,  LIU, Ping ,  CHOIDA, Marc, D. ,  DEVITA, Robert, J. ,  NARGRUND, Ravi, P. ,  GUO, Yan ,  HAMILL, Terence ,  LI, Wenping ,  HENZE, Darrell, A.

IPC分类号： A61K31/42

CPC分类号： A61K31/422 ,  A61K31/4178

摘要： The present invention is directed to a composition useful for the treatment of a FAAH mediated disease, disorder or conditions comprising a FAAH inhibitor and a second activation, comprising a selected imidazole or oxazole FAAH inhibitor and a second active agent. The compositions will be useful in the treatment of a wide range of disease, disorder, or conditions including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease. In another aspect the invention discloses herein is directed to compositions useful in the treatment of neuropathic and nociceptive pain, said compositions comprising etoricoxib.